Trials / Completed
CompletedNCT00492830
Phase 1, Open-label, Dose Escalation Study of TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1, Open-label, Dose Escalation Study of the Humanized Monoclonal Antibody, TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Tracon Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being performed to evaluate the safety and tolerability of the TRC093 antibody.
Detailed description
In addition to safety, this study will also evaluate pharmacokinetics, tumor response, and anti-TRC093 antibody formation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TRC093 recombinant humanized IgG1k monoclonal antibody | TRC093 is a humanized monoclonal antibody to cleaved collagen administered i.v. on days 1 and 15 of each 28 day cycle until pregression or unacceptable toxicity develops. |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2009-11-01
- Completion
- 2009-11-01
- First posted
- 2007-06-27
- Last updated
- 2010-02-05
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00492830. Inclusion in this directory is not an endorsement.